Plain-language overview
Semaglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist. The same molecule is FDA-approved under the brand names Ozempic (type 2 diabetes) and Wegovy (chronic weight management). It is available in an oral dissolving form (ODT) and an injectable form.
Mechanism & background
Semaglutide activates the GLP-1 receptor. In the published literature this is associated with slower gastric emptying, increased satiety, reduced appetite, and glucose-dependent insulin secretion. The combined effect is discussed in the context of appetite regulation and metabolic markers.
Class: GLP-1 receptor agonist
Where this may fit
Most often discussed for chronic weight-management and metabolic-health goals. Whether it is appropriate for any individual is a clinical decision made after review of health history, current medications, and contraindications.
Safety screening & clinician review
Every option below begins with a screening-led intake and review by a licensed clinician through our partner workflow. GI side effects (nausea, reduced appetite) are commonly described during dose titration. The class carries contraindications including a personal or family history of medullary thyroid carcinoma or MEN-2, and a noted pancreatitis consideration. Compounded availability is jurisdiction-dependent. YourHealthRx does not diagnose, prescribe, or determine dosing.